Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Ricardo J. Samms"'
Autor:
Tito Borner, Benjamin C. Reiner, Richard C. Crist, C. Daniel Furst, Sarah A. Doebley, Julia G. Halas, Minrong Ai, Ricardo J. Samms, Bart C. De Jonghe, Matthew R. Hayes
Publikováno v:
Molecular Metabolism, Vol 73, Iss , Pp 101743- (2023)
Objective: Nausea and vomiting remain life-threatening obstacles to successful treatment of chronic diseases, despite a cadre of available antiemetic medications. Our inability to effectively control chemotherapy-induced nausea and vomiting (CINV) hi
Externí odkaz:
https://doaj.org/article/1057d7b3ef0e41778c58fe147182cb30
Autor:
Ricardo J. Samms, GuoFang Zhang, Wentao He, Olga Ilkayeva, Brian A. Droz, Steven M. Bauer, Cynthia Stutsman, Valentina Pirro, Kyla A. Collins, Ellen C. Furber, Tamer Coskun, Kyle W. Sloop, Joseph T. Brozinick, Christopher B. Newgard
Publikováno v:
Molecular Metabolism, Vol 64, Iss , Pp 101550- (2022)
Objectives: Tirzepatide, a dual GIP and GLP-1 receptor agonist, delivered superior glycemic control and weight loss compared to selective GLP-1 receptor (GLP-1R) agonism in patients with type 2 diabetes (T2D). These results have fueled mechanistic st
Externí odkaz:
https://doaj.org/article/6166df01a101493baa9fce8714c6b27b
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
A major challenge of obesity therapy is to sustain clinically relevant weight loss over time. Achieving this goal likely requires both reducing daily caloric intake and increasing caloric expenditure. Over the past decade, advances in pharmaceutical
Externí odkaz:
https://doaj.org/article/74c54035c1db4e8a9fdb2e24ec53373b
Autor:
Jo E. Lewis, Chloe Monnier, Hayley Marshall, Maxine Fowler, Rebecca Green, Scott Cooper, Aristeidis Chiotellis, Jeni Luckett, Alan C. Perkins, Tamer Coskun, Andrew C. Adams, Ricardo J. Samms, Francis J.P. Ebling, Kostas Tsintzas
Publikováno v:
Molecular Metabolism, Vol 31, Iss , Pp 45-54 (2020)
Objective: Fibroblast growth factor 21 (FGF21) has been shown to rapidly lower body weight in the Siberian hamster, a preclinical model of adiposity. This induced negative energy balance mediated by FGF21 is associated with both lowered caloric intak
Externí odkaz:
https://doaj.org/article/a1e9dc6506f942278c9fc2ad5c935b3a
Autor:
Patrick J. Antonellis, Brian A. Droz, Richard Cosgrove, Libbey S. O'Farrell, Tamer Coskun, James W. Perfield, II, Steven Bauer, Mark Wade, Tara E. Chouinard, Joseph T. Brozinick, Andrew C. Adams, Ricardo J. Samms
Publikováno v:
Molecular Metabolism, Vol 30, Iss , Pp 131-139 (2019)
Objective: Fibroblast growth factor 19 (FGF19) is a postprandial hormone which plays diverse roles in the regulation of bile acid, glucose, and lipid metabolism. Administration of FGF19 to obese/diabetic mice lowers body weight, improves insulin sens
Externí odkaz:
https://doaj.org/article/f1ef67a9a6a44312b87faed6aa256893
Autor:
Jo E. Lewis, Ricardo J. Samms, Scott Cooper, Jeni C. Luckett, Alan C. Perkins, Andrew C. Adams, Kostas Tsintzas, Francis J. P. Ebling
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Abstract FGF21 exerts profound metabolic effects in Siberian hamsters exposed to long day (LD) photoperiods that increase appetite and adiposity, however these effects are attenuated in short day (SD) animals that display hypophagia and reduced adipo
Externí odkaz:
https://doaj.org/article/95e972ce73d34b99befdbcf40d02600f
Autor:
Ricardo J. Samms, Dennis P. Smith, Christine C. Cheng, Patrick P. Antonellis, James W. Perfield 2nd, Alexei Kharitonenkov, Ruth E. Gimeno, Andrew C. Adams
Publikováno v:
Cell Reports, Vol 11, Iss 7, Pp 991-999 (2015)
A primary target of the pleiotropic metabolic hormone FGF21 is adipose tissue, where it initiates a gene expression program to enhance energy expenditure, an effect presumed to be centered on augmented UCP1 expression and activity. In UCP1 null (UCP1
Externí odkaz:
https://doaj.org/article/3d27427d33034b5a8636289a607e3145
Autor:
Ricardo J. Samms, Christine C. Cheng, Marcel Fourcaudot, Sami Heikkinen, Ahmed Khattab, John Adams, Eugenio Cersosimo, Curtis Triplitt, Curtis Puckett, Kostas Tsintzas, Andrew. C. Adams, Muhammad A. Abdul-Ghani, Ralph A. DeFronzo, Luke Norton
Publikováno v:
American journal of physiology. Endocrinology and metabolism. 323(2)
Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans remains largely unknown. We examined wheth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8f6cdf0e5ac4eb5707db57b31418935
https://pubmed.ncbi.nlm.nih.gov/35723225
https://pubmed.ncbi.nlm.nih.gov/35723225
Autor:
Jorge Alsina-Fernandez, Matthew R. Hayes, Arianna White, Ricardo J. Samms, Benjamin C. Reiner, Misgana Y. Ghidewon, Ankur Bamezai, Mridula Dogra, Samantha M. Fortin, Tito Borner, Caroline E. Geisler, Harvey J. Grill, Richard Cosgrove, Richard C. Crist, Jane Gaisinsky, Marcos J. Sanchez-Navarro, Sarah A. Doebley, Bart C. De Jonghe, Minrong Ai, Rosa M Leon
Publikováno v:
Diabetes. 70:2545-2553
Glucagon-like peptide 1 receptor (GLP-1R) agonists decrease body weight and improve glycemic control in obesity and diabetes. Patient compliance and maximal efficacy of GLP-1 therapeutics are limited by adverse side effects, including nausea and emes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfb9f6ef8d0bb54518f3a06649518dc2
https://doi.org/10.2337/db21-0459
https://doi.org/10.2337/db21-0459
Publikováno v:
Diabetes
During the past decade, pharmaceutical engineering of unimolecular agents has revealed the therapeutic potential of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism. From this work, one of the most intriguing findings is that enga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4166eddafe363d93b7559893b5864157
https://doi.org/10.2337/dbi21-0002
https://doi.org/10.2337/dbi21-0002